

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Brian D. Follstad

Serial No.: 10/620,064

Group Art Unit No.: 1651

Filed: July 15, 2003

Examiner: L. Lankford, Jr.

For:

METHODS AND MEANS FOR CONTROLLING SIALYLATION OF PROTEINS  
PRODUCED BY MAMMALIAN CELLS

Docket No.: 3374-A

**INFORMATION DISCLOSURE STATEMENT  
BEFORE****MAILING DATE OF EITHER A FINAL ACTION OR NOTICE  
OF ALLOWANCE (37 CFR 1.97(c))**Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, applicant submits a "List of References Cited by Applicant" on a modified PTO-1449 form and provides a copy of each of the listed references for consideration by the Examiner. This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last, but **before** the mailing date of either:

(1) a final action under § 1.113 or

10/17/2005 HTECKLU1 00000026 090089 10620064

(2) a notice of allowance under § 1.311,  
whichever occurs first.

01 FC:1806 180.00 DA

**STATEMENT OR FEE**

Accompanying this transmittal is:

A ☐ a statement as specified in 37 CFR 1.97(e):**OR**B. ☒ the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under § 1.97(c). (\$180.00).

Applicant requests consideration of this information and passage of the application to issue.

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

Oct 11, 2005

Date




Signature

**FEE PAYMENT**

Please charge Deposit Account No. 09-0089 in the amount of \$180.00 (37 CFR 1.97(c)). An original and one copy are enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 09-0089.


Respectfully submitted,



Rosemary Sweeney  
Attorney/Agent for Applicant  
Registration No.: 52,264  
Phone: (206) 265-7817  
Date: October 11, 2005

Please send all future correspondence to:

Immunex Corporation  
Law Department  
1201 Amgen Court West  
Seattle, Washington 98119-3105  
(206) 265-7000



Modified Form PTO-1449

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

3374-A

Serial No.

10/620.064

Applicant

Brian D. Follstad

Filing Date

July 15, 2003

Group

1651

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						
	A3						
	A4						
	A5						
	A6						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	B1							
	B2							
	B3							
	B4							
	B5							

**OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)**

C1	Kaufmann, H. et al., "Comparative analysis of two controlled proliferation strategies regarding product quality, influence on tetracycline-regulated gene expression, and productivity," <i>Biotechnology And Bioengineering</i> 72(6):592-602, 2001.
C2	Kawaguchi, T. et al., "A new approach to the modification of cell membrane glycosphingolipids: ganglioside composition of JTC-12 P3 cells altered by feeding with galactose as a sole carbohydrate source in protein-free and lipid-free synthetic medium," <i>Exp. Cell Res.</i> 179(2):507-516, 1988.
C3	Keppler, O. et al., "UDP-GlcNAc 2-Epimerase: A regulator of cell surface sialylation," <i>Sci.</i> 284:1372-1376, 1999.
C4	Miller-Podraza, H. et al., "Biosynthesis and localization of gangliosides in cultured cells," <i>Biochem.</i> 21(14):3260-3265, 1982.
C5	Stephanopoulos, G. and Vallino, J., "Network rigidity and metabolic engineering in metabolite overproduction," <i>Science</i> 252:1675-1681, 1991.
C6	Vriezen, N. and van Dijken, J., "Fluxes and enzyme activities in central metabolism of myeloma cells grown in chemostat culture," <i>Biotech. &amp; Bioeng.</i> 59(1):28-39, 1998.
C7	Wang, D., "Engineering of CHO cell glycosylation through CMP-Sialic acid transporter over expression," <i>Biochemical Engineering XIV, Session VI - Physiology of Protein Expression</i> , Engineering Conferences International, Harrison Hot Springs, BC, Canada, July 10-14, 2005.
C8	Yoon Sung Kwan et al., "Effect of low culture temperature on specific productivity and transcription level of anti-4-1BB antibody in recombinant Chinese hamster ovary cells," <i>Biotech. Progress</i> 19(4):1383-1386, 2003.
C9	Zanghi, J. et al., "Role of nucleotide sugar pools in the inhibition of NCAM polysialylation by ammonia," <i>Biotech. Progress</i> 14(6):834-844, 1998.

EXAMINER:

Date Considered: